Oct 10, 2025

The partnership will leverage Turbine’s platform and its capacity to streamline the ADC discovery process. October 10, 2025 Turbine and AstraZeneca previously partnered to investigate mechanisms of therapy resistance in haematological cancers. Turbine and AstraZeneca have entered a partnership to enhance the discovery of antibody-drug conjugates (ADCs) using the former’s virtual disease models. Free Report Unlocking ADC Innovation: Optimizing Payload, Linker, and Target Selection for Better Therapeutic Outcomes Explore how next-generation antibody–drug conjugates (ADCs) are transforming oncology and beyond. Download now to learn how innovations are optimising payload, linker, and target selection to deliver safer, more effective therapies. Thank you. Go deeper with GlobalData Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms. Submit By downloading this Report, you acknowledge that GlobalData may share your information with Syngene Thematic and that your personal data will be used as described in their Privacy Policy Tick here to opt out of curated industry news, reports, and event updates Submit Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. The partnership will leverage Turbine’s platform to predict response mechanisms, optimise ADC positioning, and reduce reliance on extensive cell line screening. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData It will leverage Turbine’s ability to virtualise biological experiments to streamline the ADC discovery process while providing mechanistic insights. Turbine and AstraZeneca previously partnered to investigate mechanisms of therapy resistance in haematological cancers using Turbine’s Simulated Cell platform. This earlier partnership also focused on predicting combination synergy and identifying relevant biomarker candidates linked to DNA damage repair mechanisms. Turbine chief scientific officer and co-founder Daniel Veres stated: “By implementing a lab-in-the-loop approach, we can move beyond broad experimental screening toward a more efficient, targeted strategy that selects the ADC combinations most likely to succeed in patients. “This also lays the groundwork for deeper integration of our Virtual Lab into discovery workflows, helping ensure that the right experiments are run to generate the greatest impact for patients.” The companies plan to adopt a lab-in-the-loop approach to address the challenge in ADC development. This method involves Turbine’s platform, suggesting a selected subset of cell lines for testing, followed by predicting outcomes across thousands of in silico models using AstraZeneca’s ADC datasets. These datasets encompass both single-agent and combination studies, bringing discovery efforts closer to clinical outcomes. The long-term goal of the initiative is to extend similar methodologies to patient-derived models and ultimately enhance clinical care. In addition to alleviating the experimental burden, Turbine’s platform offers mechanistic insights that improve clinical translatability. The platform not only models cell survival but also alters gene expression, facilitating a better understanding of why certain cells respond to or resist treatment. Earlier in 2025, AstraZeneca, Tempus and Pathos AI partnered to develop a large-scale multimodal deep learning model designed to accelerate cancer drug discovery . ADC content on Pharmaceutical Technology (Or Clinical Trials Arena) is supported by Syngene. Editorial content is independently produced and follows the  highest standards  of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Report Unlocking ADC Innovation: Optimizing Payload, Linker, and Target Selection for Better Therapeutic Outcomes Explore how next-generation antibody–drug conjugates (ADCs) are transforming oncology and beyond. Download now to learn how innovations are optimising payload, linker, and target selection to deliver safer, more effective therapies. Thank you.